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pAbstract
Background: Lethal and edema toxin contribute to shock and lethality with Bacillus
anthracis. We showed previously in a 96-h sedated canine model that raxibacumab, a
monoclonal antibody against protective antigen, augmented hemodynamic support (HS)
and improved survival with lethal toxin challenge. Here we study raxibacumab further.
Using this model, we have now studied raxibacumab with 24 h edema toxin challenges
(Study 1), and lethal and edema toxin challenges together (Study 2).
Methods: Using our canine model, we have now studied raxibacumab with 24h edema
toxin challenges (Study-1), and lethal and edema toxin challenges together (Study-2).
Results: In Study 1, compared to no treatment, HS (titrated fluid and norepinephrine)
increased mean arterial blood pressure (MAP, p ≤ 0.05) but not survival [0 of 10 (0/10)
animals survived in each group] or median survival time [43.8 h (range 16.8 to 80.3) vs.
45.2 h (21.0 to 57.1)]. Compared to HS, HS with raxibacumab treatment at or 6 h after the
beginning of edema toxin increased MAP and survival rate (6/7 and 7/8, respectively) and
time [96.0 h (39.5 to 96.0) and 96.0 h (89.5 to 96.0), respectively]; (p ≤ 0.05). HS with
raxibacumab at 12 h increased MAP (p≤ 0.05) but not survival [1/5; 55.3 h (12.6 to 96.0)].
In Study-2, survival rate and time increased with HS and raxibacumab at 0 h (4/4) or 6 h
after (3/3) beginning lethal and edema toxin compared to HS [0/5; 71.5 h (65 to 93)]
(p = 0.01 averaged over raxibacumab groups).
Conclusions: Raxibacumab augments HS and improves survival during shock with lethal
and edema toxin.
Keywords: B. anthracis; Edema toxin; Lethal toxin; Monoclonal antibody; Protective
antigen; RaxibacumabBackground
During recent outbreaks of Bacillus anthracis infection in developed countries, mortality
rates in patients with shock have been close to 80% [1-4]. By comparison, mortality from
shock due to other types of bacterial infection is reported to be 20 to 50% [5-8]. Adjunctive
therapies that augment conventional hemodynamic support (HS) during B. anthracis shock
may improve outcomes from this lethal infection.2015 Remy et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution
icense (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
rovided the original work is properly credited.
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[9-11], each consisting of a toxic moiety [lethal factor (LF) and edema factor (EF), re-
spectively] and protective antigen (PA), which mediates transport of the toxic moieties
into host cells. Lethal factor is a metalloprotease that blocks mitogen-activated protein
kinase kinases and stimulates inflammasome formation [4,12,13]. Edema factor is a
calmodulin-dependent adenylyl cyclase that increases intracellular cAMP levels [14-17].
Although on a weight basis LT is five to ten times more lethal than ET, both toxins are
thought to contribute to shock during infection with B. anthracis [18-20].
We previously developed a 96 h sedated, instrumented, and ventilated canine model of
B. anthracis toxin-associated shock in which LT or ET was infused over 24 h to simulate
release during infection [18]. In this model, lethal doses of the two toxins had very
different hemodynamic effects. While both caused hypotension that persisted for 96 h, LT
produced myocardial dysfunction while ET produced marked arterial dilation. In this
model, a non-lethal dose of ET augmented the lethal effects of LT [18].
We subsequently employed this model to investigate the treatment with hemodynamic
support (titrated normal saline and norepinephrine infusions, HS) alone or together with
raxibacumab (raxi), a PA-directed monoclonal antibody (originally Human Genome
Sciences and now GlaxoSmithKline, Rockville, MD, USA) for LT-associated shock [21]. By
targeting PA in the extracellular space, raxi inhibits the two toxins by blocking host cell
internalization of the toxic moieties LF and EF, which is necessary for toxin activity
[22-25]. Hemodynamic support alone produced a small but significant increase in survival
[21]. However, compared to HS alone, HS with raxi administered either at the start of LT
or 9 or 12 h later, promoted fluid mobilization, increased blood pressure, reduced vaso-
pressor requirements, and improved myocardial function and survival [21]. Since raxi has
now been added to the Strategic National Stockpile but has not been tested clinically dur-
ing B. anthracis-associated shock, we employed this canine model to also investigate the
effects of HS alone or together with raxi for shock caused by lethal ET challenge in one
study (Study-1) and lethal challenge with LT combined with a similar weight dose of ET
in another study (Study-2). We hypothesized that HS with raxi would improve survival
and hemodynamics compared to HS in shock from ETalone or LT and ET together.
Methods
Study design
The National Institutes of Health Clinical Center Animal Care and Use Committee ap-
proved these studies as protocol CCM1201. Four purpose-bred beagles (weighing 10 to
12 kg) prepared as previously described with tracheostomy tubes and venous, pulmon-
ary and systemic arterial, and urinary catheters, were studied weekly [18]. Sedation,
maintenance fluids, and mechanical ventilation were applied similarly to all groups
using standardized ICU protocols [21,26].
In Study 1, starting at 0 h (T0), all animals were challenged with a 24 h ET infusion
(Figure S1A in Additional file 1). Ten weekly experiments were conducted. Each week,
in the first six experiments, four animals were randomized at the start of ET infusion
to: no treatment (fixed maintenance fluid only), hemodynamic support alone (HS, fluid
and norepinephrine titrated to pulmonary, and systemic arterial pressures, respectively),
or HS combined with a single dose of raxi administered either at the start of ET (HS +
mAbT0) or 12 h later (HS+ mAbT12) (Figure 1A). Based on the results of these six
Figure 1 Survival Times and the proportion of animals surviving over time. This figure shows the
individual survival times for each of the animals assigned to no treatment (maintenance fluid only),
hemodynamic support alone (HS; fluids and norepinephrine titrated to pulmonary artery wedge pressure and
mean arterial blood pressure, respectively), or HS combined with raxibacumab administered at the start of (HS
+mAbT0) or 6 h (HS +mAbT6) or 12 h (HS +mAbT12) after the start of edema toxin (ET) infusion in each of the
ten weekly experiments comprising Study 1 (A) (see Methods). This figure also shows the proportion of animals
surviving over time in experiments 1 to 6 (B), 7 to 10 (C), and for all ten experiments together (D). In experiment
3, an animal randomized to receive HS + mAbT12 received HS + mAbT0 instead.
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were randomized to no treatment (n = 1), HS alone (n = 1), or HS combined with raxi
administered 6 h after the start of ET (HS +mAbT6) (n = 2).
In Study 2, four animals were challenged weekly with a lethal dose of LT combined
with a similar weight dose of ET administered as 24 h infusions (Figure S1B in
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effects on lethality compared to LT alone [18]. At the start of toxin infusion, animals
were randomized to receive HS alone or HS combined with raxi administered at 0 h
(HS +mAbT0) or 6 h (HS + mAbT6). As described in the results, after completion of
three experiments, this study was concluded and data were analyzed.
Hemodynamic monitoring was started at 0 h and continued until the end of both
Studies 1 and 2 (Figure S1A and B in Additional file 1). Cardiopulmonary and other la-
boratory measures were obtained immediately before and at regular intervals after initi-
ation of toxin. Whereas blood pressure, heart rate (HR), temperature, and oxygen
saturation were continuously monitored, central venous pressure (CVP) was recorded
every 2 h, and pulmonary capillary wedge pressure (PCWP) was measured every 2 h
for the first 8 h, and every 4 h thereafter. Arterial blood gases (ABGs) were obtained
every 2 h for the first 8 h and every 8 h or as needed based on protocol thereafter. Left
ventricular ejection fraction (LVEF), measured by echocardiography, and chemistry and
complete blood count data were obtained at 24 h intervals. Total fluid intake was
recorded every 2 h, whereas urine output was recorded every 24 h and at time of death.
Norepinephrine requirements were recorded hourly. Surviving animals were euthanized
at 96 h after measurements were completed.
Toxin and treatments
Lethal and edema toxins were prepared as previously described and administered in
doses designed to produce lethality rates greater than 75% [18]. In Study 1, the ET
challenge consisted of PA, 410 μg/kg, and EF, 205 μg/kg; while in Study 2, LT and ET
challenge together consisted of PA, 10 μg/kg, LF, 10 μg/kg, and EF, 10 μg/kg. The raxi
dose employed in both studies (ten times the molar amount of PA administered to each
animal) was administered as a single dose, 2 mL intravenous injection at the specified
times (Figure S1 in Additional file 1). Animals not assigned to raxi treatment concur-
rently received a similar volume of a human inactive, non-specific iso-matched IgG1
monoclonal antibody (mAb CAT002 lot number: AG-193-73-M4L originally Human
Genome Sciences and now GlaxoSmithKline, Rockville, MD, USA) which had been
used in our previous study [21].
To ensure that animals studied had similar starting preload; at baseline, all animals
had one to three boluses (20 mL/kg) of normal saline as needed until a PCWP
of ≥10 mmHg was achieved. Thereafter, animals receiving HS were administered a
single bolus of 20 mL/kg normal saline if the PCWP (note times above) was found to
be <10 mmHg. Additionally, if at any time, the mean arterial blood pressure (MAP) de-
creased to <80 mmHg for >5 min, norepinephrine infusion was initiated at 0.2 μg/kg/
min and, if necessary, increased in a stepwise fashion to 0.6, 1, or a maximum of 2 μg/
kg/min, every 5 minutes (and similarly titrated down if MAP was >100 mmHg
for >5 min). Animals in the no treatment group in Study 1 had measures performed
but did not receive titrated fluid or norepinephrine. Technicians blinded to raxi alloca-
tion administered all supportive therapies.
Ventilator management, temperature control, and sedation with midazolam, fentanyl,
and medetomidine were managed uniformly for all groups based on previously reported
protocols [26]. Stepwise ventilator adjustments were made to FiO2, positive end-
expiratory pressure, and respiratory rate based on continuous pulse oximetry and
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(Normosol-M at 3 mL/kg/h for the first 36 h, 2 mL/kg/h for the next 36 h, and then
1 mL/kg/h until study completion) [26]. Additional care for all animals included pharma-
cologic prophylaxis for gastrointestinal stress ulcers (famotidine) and deep venous throm-
bosis (heparin subcutaneously) and ceftriaxone to prevent catheter-related infections [26].
Statistical methods
Survival times between the two treatment groups were compared using exact log-rank
tests (StatXact, Cytel Software Corp., Cambridge, MA). For all other variables, the
change-from-baseline values for individual animals were compared unless there was no
baseline value collected. To evaluate shock reversal, we standardized MAP and nor-
epinephrine using Z-scores and then calculated a ‘shock reversal’ score (designated
shock index) based on the difference of the MAP Z-score and norepinephrine Z-score,
with a higher score indicating improved hemodynamics. Linear mixed models (SAS
PROC Mixed, SAS version 9.3, Cary, NC) were used to compare the change from base-
line values of different treatments for each time point. All animals were analyzed in the
model, and the correlation of animals within each week was accounted for in the model
as a random effect. Standard residual diagnostics were used to check model assump-
tions. Two-sided p values of 0.05 or less were considered significant without adjusting
for multiple comparisons.
Results
Study 1: Effect of hemodynamic support alone or together with PA-mAb during
challenge with edema toxin
Survival
A total of 40 animals were challenged with 24 h ET infusions in ten weekly experi-
ments (four animals per experiment). Over these experiments, all ten animals receiving
no treatment (maintenance fluid only) and all ten animals receiving HS alone (see
Methods) died with median survival times (ranges) of 45.2 h (21.0 to 57.1) and 43.8 h
(16.8 to 80.3), respectively (p = 0.61) (Figure 1). In experiments 1 to 6, six of seven
animals receiving HS and raxi administered at 0 h (HS +mAbT0) survived while only
one of five animals receiving HS and raxi administered at 12 h (HS +mAbT12) sur-
vived, with the median survival times of 96.0 h (39.5 to 96.0) and 55.3 h (12.6 to 96.0),
respectively. Compared to HS alone in experiments 1 to 6, HS + mAbT0 improved
survival significantly (p = 0.02) but HS + mAbT12 did not (p = 0.19). To conserve ani-
mals but still explore the potential benefit of delayed raxi treatment (<12 h after
toxin infusion), in experiments 7 to 10, animals were randomized each week to no
treatment (n = 1), HS alone (n = 1), or HS with raxi administered 6 h after the start of
ET (HS +mAbT6, n= 2). In these experiments, seven of eight animals receiving HS +mAbT6
survived with a median survival time of 96.0 h (89.5 to 96.0), and this was significantly
better than HS alone (p = 0.01).
Other laboratory data
Since few animals receiving no treatment or HS alone were alive for comparison after
48 h from Study 1 (Figure 1), analysis was conducted over the initial 48 h as lethality
developed. To first determine whether there was any evidence of benefit with HS alone,
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with raxi administered at each of the three treatment times were compared to HS alone
(Figures 3, 4, and 5).
Compared to no treatment, HS animals had increased fluid intake at 24 and 48 h and
increased fluid (urine) output at 24 h (all p ≤ 0.05), but no significant difference in net
fluid balance (Figure 2). Norepinephrine was administered to HS animals by 6 h and




Figure 2 Serial mean changes for HS animals vs. controls. This figure compares the serial mean (±SEM)
changes from baseline in fluid in (A), fluid out (B), net fluid (C), pulmonary capillary wedge pressure (PCWP) (D),
mean arterial blood pressure (E; MAP), heart rate (F; HR), lactate (G), blood urea nitrogen (H; BUN), creatinine (I),
chloride (J), pH (K), and alveolar to arterial oxygen gradient (L; AaO2) for animals challenged with edema toxin
and receiving no treatment (maintenance fluid only) versus hemodynamic support alone (HS; fluids and
norepinephrine titrated to pulmonary artery wedge pressure and mean arterial blood pressure, respectively) in
Study 1. Units of measure are shown in each panel. *p≤ 0.05, **p < 0.0001.
Figure 3 Serial mean changes in fluids and hemodynamics for HS. vs. raxibacumab animals in study 1.
This figure compares the serial mean (±SEM) changes from baseline in fluid in (A), fluid out (B), net fluid (C),
pulmonary capillary wedge pressure (PCWP) (D), norepinephrine use (NE) (E), mean arterial blood pressure (MAP)
(F), shock index score (G), heart rate (HR) (H), left ventricular ejection fraction (LVEF) (I), central venous pressure
(CVP) (J), cardiac index (CI) (K), and systemic vascular resistance (SVR) (L) for animals receiving hemodynamic
support alone (HS, fluids and norepinephrine titrated to pulmonary artery wedge pressure and mean arterial
blood pressure, respectively) versus HS combined with raxibacumab administered at the start of (HS +
mAbT0) or 6 h (HS + mAbT6) or 12 h (HS + mAbT12) after the start of edema toxin challenge in Study 1.
Units of measure are shown in each panel (except for shock index score). *p ≤ 0.05, **p < 0.0001.
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18, 30, and 42 h, and (possibly related to the maximum norepinephrine dose HS ani-
mals received) HR at 12 to 48 h (p ≤ 0.05) (Figure 2). Consistent with treatment and
improved hemodynamics, HS decreased lactate at 32 and 40 h, blood urea nitrogen
(BUN) levels at 24 and 48 h, and creatinine (Cr) at 48 h. HS also increased chloride
(Cl−) at 24 and 48 h and sodium (Na+) at 24 h (p ≤ 0.05, data for Na+ not shown).
Figure 4 Serial mean changes in electrolytes for HS. vs. raxibacumab animals in study 1. This figure
compares the serial mean (±SEM) changes from baseline in sodium (A), chloride (B), potassium (C), blood
urea nitrogen (BUN) (D), creatinine (E), total protein (TP) (F), aspartate aminotransferase (AST) (G), lactate
dehydrogenase (LDH) (H), and creatine kinase (CK) (I) for animals receiving hemodynamic support alone
(HS, fluids and norepinephrine titrated to pulmonary artery wedge pressure and mean arterial blood
pressure, respectively) versus HS combined with raxibacumab administered at the start of (HS +mAbT0) or
6 h (HS +mAbT6) or 12 h (HS +mAbT12) after the start of edema toxin challenge in Study 1. Units of
measure are shown in each panel *p ≤ 0.05, **p < 0.0001.
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pH at 6 to 24 h (except 12 h), and bicarbonate (HCO3−) at 8 to 16 h, possibly due to
the normal saline administered (p ≤ 0.05, ABE and HCO3− not shown). Notably, HS
significantly decreased arterial oxygen (PaO2) and increased alveolar to arterial oxygen
gradient (AaO2) at 40 h (p ≤ 0.05, data for PaO2 not shown). As shown in Figure 2, the
significant effects of HS on MAP, lactate, BUN, and Cr resulted in changes closer to
baseline values than in controls not receiving treatment.
We next compared the effect of HS combined with raxi versus HS alone (Figures 3,
4, and 5). Since HS +mAbT0 and HS +mAbT6 both significantly increased survival
compared to HS, while HS +mAbT12 did not, data are first presented for the two earl-
ier raxi treatment groups. Compared to HS alone, HS +mAbT0 and HS +mAbT6 in-
creased fluid (urine) output and net negative fluid balances at 48 h (p ≤ 0.05) (Figure 3).
Pulmonary capillary wedge pressure did not differ significantly between groups. Treat-
ment with HS +mAbT0 and HS +mAbT6 decreased norepinephrine requirement,
Figure 5 Serial mean changes in ABG data for HS. vs. raxibacumab animals in study 1. This figure
compares the serial mean (±SEM) changes from baseline in pH (A), HCO3
− (B), arterial base excess (ABE) (C),
lactate (D), PaCO2 (E), and alveolar to arterial oxygen gradient (AaO2) (F) for animals receiving hemodynamic
support alone (HS, fluids and norepinephrine titrated to pulmonary artery wedge pressure and mean arterial
blood pressure, respectively) versus HS combined with raxibacumab administered at the start of (HS +mAbT0)
or 6 h (HS +mAbT6) or 12 h (HS +mAbT12) after the start of edema toxin challenge in Study 1. Units of
measure are shown in each panel *p ≤ 0.05, **p < 0.0001.
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tween 12 and 48 h (p ≤ 0.05), although these effects occurred earlier and were more
pronounced with HS +mAbT0. Both HS +mAbT0 and HS +mAbT6 increased left ven-
tricular ejection fraction (LVEF) at 24 h, total protein and albumin at 48 h, and
decreased BUN, Cr, potassium (K+), aspartate amino-transaminase (AST), and lactate
dehydrogenase (LDH) at 24 and/or 48 h and creatine kinase (CK) at 12 h (p ≤ 0.05 for
all) (Figures 3 and 4, data for albumin not shown). While HS +mAbT0 and HS +
mAbT6 had variable effects early on ABE, pH, and HCO3−, both increased these sig-
nificantly at multiple time points from 12 to 48 h (p ≤ 0.05) (Figure 5). Both treatments
also increased PaO2 and decreased AaO2 at either 40 or 48 h (p ≤ 0.05, data for PaO2
not shown). Compared to HS alone, HS +mAbT0 also decreased fluid intake and out-
put at 24 h, increased CVP from 6 to 18 h and 30 to 36 h, decreased cardiac index (CI)
and increased systemic vascular resistance (SVR) from 6 to 24 or 48 h, increased Na+
at 6 to 24 h and Cl− at 6 to 12 h, decreased arterial carbon dioxide (PaCO2) at 40 to
48 h and first increased lactate at 12 h and then decreased it at 24 and 40 h (p ≤ 0.05).
Compared to HS alone, HS +mAbT6 decreased Cl− at 48 h and increased PaCO2 at
8 to 24 h.
Compared to HS alone, HS +mAbT12 increased fluid intake at 48 h and output at
24 h (both p ≤ 0.05), but did not alter net fluid balance. Animals receiving HS +
mAbT12 required increasing doses of norepinephrine just like HS alone animals and
had modest increases in MAP (significant at 36 h, p = 0.05), although shock index
scores did not differ significantly. Moreover, HS +mAbT12 treatment was associated
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and 32 h, increased PaO2 at 48 h and decreased AaO2 at 24, 40, and 48 h (all p ≤ 0.05,
data for PaO2 not shown).
As shown in Figures 3, 4, and 5, the effects of either HS +mAbT0, HS +mAbT6, or
HS +mAbT12 that were significant on norepinephrine requirements, MAP, Shock
Index, HR, LVEF, CVP, CI, SVR, Na+, K+, BUN, Cr, protein, ASL, lactate, CK, pH,
HCO3, ABE, lactate, or AaO2 resulted in changes closer to baseline values than in ani-
mals receiving HS alone.
Study 2: Effect of hemodynamic support alone or together with PA-mAb during
challenge with lethal and edema toxin together
Survival
Twelve animals were challenged with 24 h infusions of LT and ET together in three
weekly experiments (four animals per experiment). Five animals were treated with HS
alone, and four and three were treated with HS combined with raxi administered at 0
or 6 h, respectively (Figure 6A). While all animals receiving HS alone died with a me-
dian survival time (range) of 71.5 h (65 to 93 h), all animals receiving HS with raxi at
either 0 or 6 h survived for 96 h (Figure 6A and B). Since these effects on survival were
very similar to those observed with HS with raxi treatment during challenge with ET
or LT alone (see above for ET and reference 21 for LT), further experiments were not
conducted and data from animals receiving raxi at the two treatment times were com-
bined in survival and other data analysis. Compared to HS alone, animals receiving HS
with raxi at 0 or 6 h (HS +mAbT0/T6) had significantly improved survival (p = 0.01).
Other laboratory data
Due to longer survival with HS alone in Study 2, other laboratory data were examined
over the entire 96 h observation period. Compared to HS alone, HS +mAbT0/T6 signifi-
cantly increased fluid (urine) output at 48 and 96 h and net negative fluid balance at 48 h,
decreased norepinephrine requirements at 54 to 90 h (except 78 h), increased MAP at 72
and 84 h and shock index score at 54 and 66 to 90 h (except 78 h) (Figure 6C to H),
decreased HR at 54 to 78 h, and increased CVP at 60 to 72 and 90 h (p ≤ 0.05) (Figure 6C
to H, HR and CVP data not shown). Compared to HS alone, HS + mAbT0/T6 also in-
creased Cl− at 6, 12, and 24 h and ABE and HCO3− at 56, 64, and 88 h and decreased
AaO2 at 48, 56, and 64 h and PT at 72 h (p ≤ 0.05, data not shown). As shown in
Figures 6, the effects of HS + mAbT0 and HS +mAbT6 on norepinephrine require-
ments, MAP, and Shock Index resulted in changes closer to baseline values than in
animals receiving HS alone. Such changes were also the case for ABE, HCO3−, AaO2,
and PT (not shown).
Discussion
In summary, without any treatment in Study 1, 24 h ET challenge produced 100%
lethality. Treatment with HS alone produced smaller decreases in blood pressure, but
did not improve survival from ET challenge. However, HS combined with raxi at either
0 or 6 h but not at 12 h, improved survival significantly compared to HS alone. Simi-
larly in Study 2, with LT and ET challenge together, HS combined with raxi at 0 or 6 h
increased survival significantly.
Figure 6 Survival times and the proportion of animals surviving over time and serial mean changes
in parameters in study 2. This figure shows the individual survival times for each of the animals assigned
to hemodynamic support alone (HS; fluids and norepinephrine titrated to pulmonary artery wedge pressure
and mean arterial blood pressure, respectively) and HS combined with raxibacumab administered at the
start of (HS +mAbT0) or 6 h after (HS +mAbT6) after the start of lethal and edema toxin infusion in each of
the three weekly experiments comprising Study 2 (A). This figure also shows the proportion of animals
surviving over time in these three experiments combined (B). Finally, this figure compares the serial mean
(±SEM) changes from baseline in fluid in (A), fluid out (B), net fluid (C), norepinephrine requirement (NE)
(D), mean arterial blood pressure (MAP) (E), and shock index score (F), for animals receiving hemodynamic
support alone (HS, fluids and norepinephrine titrated to pulmonary artery wedge pressure and mean
arterial blood pressure, respectively) versus combined with protective antigen directed monoclonal
antibody administered at the start of (HS +mAbT0) or 6 h (HS +mAbT6) after the start of lethal and edema
toxin challenge in Study-2. In panels C-H, the two raxibacumab groups are combined and designated HS
+mAb. *p≤ 0.05, **p < 0.0001.
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alone did not improve survival in Study 1 from a similarly lethal ET challenge. Several
reasons could account for this difference [21]. First, while lethality with ET was evident
before challenge was completed (<24 h), with LT the first death didn’t occur until 24 h
after challenge. Thus, the rapidity of lethality with ET may have negated any beneficial
survival effect with HS. Second, in a rat aortic ring model, treatment with lethal con-
centrations of ET but not LT inhibited the contractile response of rings to phenyleph-
rine [27]. In this canine model, ET may have similarly directly inhibited the beneficial
vasopressor effects of norepinephrine. Finally, treating shock from ET challenge with
HS alone produced hypoxemia. Although ET has generally not produced gas exchange
abnormalities in animal models, fluids in HS may have aggravated ETs edema produ-
cing actions. Such an effect could have worsened oxygenation and negated benefit with
HS. Previously, HS did not worsen oxygenation during LT challenge [18,21].
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significantly increased survival. This survival benefit was associated with increased
urine output and net negative fluid balance, reduced vasopressor requirements, and im-
proved blood pressure, shock index score, oxygenation, and organ function (i.e., reduced
BUN, Cr, and AST). Furthermore, HS with raxi at the start of ET challenge reduced fluid
intake at 24 h, while increasing CVP and SVR. The basis for these effects of HS combined
with raxi is likely related to evidence that ET contributes to shock via at least two mecha-
nisms. First, ET weakens the adherens junctions connecting endothelial cells and pro-
motes extravasation of fluid and solute [28-30]. Inhibition of ET and improved endothelial
barrier function would provide a basis for the decreased fluid requirement and net
negative fluid balance, increased CVP, and improved oxygenation noted with HS and raxi
compared to HS alone. Secondly, ET may also cause direct arterial relaxation and inhibit
arterial contractile responses to catecholamines [31]. Inhibition of these ET effects
provides a basis for the reduced norepinephrine requirements and increased MAP, shock
index, and SVR noted with HS and raxi compared to HS alone.
Although HS with raxi administered at 12 h after starting ET challenge was associ-
ated with a small increase in survival, this was not significant. Thus, in contrast to HS
with raxi at 6 h, the rapidity of ETs lethal effects may have limited benefit with delayed
treatment at 12 h. By contrast, with LT challenge previously in which lethality was not
evident until 48 h, treatment with HS and raxi as late as 12 h did significantly improve
survival [21]. Notably though, in the present study with ET, HS with raxi at 12 h did
produce small increases in blood pressure, reductions in AST, and improved
oxygenation.
It is possible that even without HS; raxi might have been beneficial with ET in Study
1. However, in a previous LT challenge study using this same model, raxi lacked any
benefit when administered alone after 0 h but was beneficial for up to 12 h when
combined with HS [21]. That finding suggested that HS augmented the effects of raxi,
possibly by promoting its tissue distribution. Based on these prior results and because
patients with B. anthracis shock would typically receive hemodynamic support, we did
not test raxi alone in the present study.
In Study 2, HS combined with raxi at 0 or 6 h was also beneficial with LT and ET
together, improving urine output and net negative fluid balance and reducing norepin-
ephrine requirements while increasing MAP, shock index score, and survival. Although
the number of animals studied was relatively small, the results of Study 2 were very
similar to those observed with HS and raxi with either lethal ET challenge in Study 1
or with lethal LT challenge in our prior study [21]. From an animal care and usage
standpoint, additional experiments were not appropriate. However, the findings from
these three studies together (Studies 1 and 2 here, and a prior LT alone study) provide
evidence that agents inhibiting LT and ET may be beneficial when added to conven-
tional hemodynamic support for shock caused by these toxins during B. anthracis
infection. Such benefit may be twofold, inhibiting organ injury related directly to the
toxins and lowering adverse effects of conventional treatments (e.g., fluid overload or
vasopressor-induced ischemic injury).
This study has limitations. First, other pathogenic mediators, such as bacterial cell
wall and non-toxin proteases, likely contribute to shock with B. anthracis infection [4].
Whether hemodynamic support and raxi would have additive benefit during shock
Remy et al. Intensive Care Medicine Experimental  (2015) 3:9 Page 13 of 14related to these other pathogenic mediators is unclear. Second, hemodynamic support
in the present study was restricted to fluid and norepinephrine administration. Other
vasopressors or inotropes such as phenylephrine, vasopressin, or dobutamine might
also have beneficial effects in combination with raxi or other PA directed agents.Conclusion
In conclusion, both LT and ET are thought to contribute to shock and organ injury during
severe B. anthracis infection. Our findings in this canine model suggest that inhibition of
these toxins with PA directed monoclonal antibodies such as raxi likely adds to the benefit
of conventional treatments.
Additional file
Additional file 1: Figure S1. This figure shows the time lines of experimental interventions, measurements, and
treatments for Study 1 (A) and Study 2 (B). As outlined in ‘Methods’, in Study 1 at the initiation of 24 h edema
toxin infusion, animals were randomized to receive hemodynamic support alone, hemodynamic support in
combination with protective antigen directed monoclonal antibody (PA-mAb) administered at the time of (0 h) or
6 or 12 h after starting toxin infusion, or no treatment. Hemodynamic support included a single bolus of 20 mL/kg
of normal saline if the pulmonary artery occlusion pressure (PAOP, checked every 2 h for the first 8 h and every
4 h thereafter) was <10 mmHg. Also, if at any time mean arterial blood pressure (MAP) decreased to <80 mmHg
for >5 min, a norepinephrine infusion was initiated at 0.2 μg/kg/min and, if necessary, increased in a stepwise
fashion every 5 min to 0.6 to 1 or a maximum of 2 μg/kg/min. Norepinephrine was titrated down in a step-wise
fashion if MAP was greater than 100 mmHg for >5 min. Other abbreviations: HR, heart rate; CVP, central venous
pressure; LVEF, left ventricular ejection fraction (measured with echocardiography); CBC, complete blood count;
ABG, arterial blood gas. In Study 2, animals were challenged with lethal toxin and edema toxin in combination and
were randomized to treatment with hemodynamic support alone or hemodynamic support combined with
PA-mAb administered at the time of or 6 h after the start of toxin. Other measurements and treatments were
similar to Study 1.
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